Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.

ABSTRACT:

Introduction

Screening potential participants in Alzheimer's disease (AD) clinical trials with amyloid positron emission tomography (PET) is often time consuming and expensive.

Methods

A web-based application was developed to model the time and financial cost of screening for AD clinical trials. Four screening approaches were compared; three approaches included an AD blood test at different stages of the screening process.

Results

The traditional screening approach using only amyloid PET was the most time consuming and expensive. Incorporating an AD blood test at any point in the screening process decreased both the time and financial cost of trial enrollment. Improvements in AD blood test accuracy over currently available tests only marginally increased savings. Use

SUBMITTER: Schindler SE 

PROVIDER: S-EPMC9902574 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature